Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Moya‑Alarcón, C. (Carlota) | - |
dc.creator | González‑Domínguez, A. (Almudena) | - |
dc.creator | Simón, S. (Susana) | - |
dc.creator | Pérez‑Román, I. (Inés) | - |
dc.creator | González-Martín, A. (Antonio) | - |
dc.creator | Bayo‑Lozano, E. (Eloisa) | - |
dc.creator | Sánchez‑Heras, A.B. (Ana Beatriz) | - |
dc.date.accessioned | 2021-09-20T09:37:24Z | - |
dc.date.available | 2021-09-20T09:37:24Z | - |
dc.date.issued | 2019 | - |
dc.identifier.citation | Moya‑Alarcón, C. (Carlota); González‑Domínguez, A. (Almudena); Simón, S. (Susana); et al. "Cost–utility analysis of germline BRCA1/2 testing in women with high‑grade epithelial ovarian cancer in Spain". Clinical and Translational Oncology. 21, 2019, 1076 - 1084 | es_ES |
dc.identifier.issn | 1699-048X | - |
dc.identifier.other | PMID: 30617925 | - |
dc.identifier.uri | https://hdl.handle.net/10171/62027 | - |
dc.description.abstract | Purpose: Germline mutations in BRCA1 and/or BRCA2 genes (gBRCA1/2m) are associated with an increased risk of breast cancer (BC) and ovarian cancer (OC). The aim of this study was to estimate the efficiency of providing germline BRCA1/2 testing to high-grade epithelial ovarian cancer (HGEOC) patients without family history of OC or BC and the subsequent testing and management of their relatives with gBRCA1/2m in Spain. Methods/patients: Incident HGEOC patients without family history of OC or BC who were gBRCA1/2m carriers and their relatives were simulated in a 50-year time horizon. The study compared two scenarios: BRCA1/2 testing vs no testing, using the perspective of the Spanish National Health Service. Cancer risk among gBRCA1/2m carriers was estimated based on their age and whether they had undergone risk-reducing surgeries. Direct healthcare costs and utilities of patients who developed EOC and BC were also included. A probabilistic sensitivity analysis (PSA) with 5 thousand simulations was developed considering ± 25% of the base-case value. Results: The BRCA1/2-testing scenario amounted to €13,437,897.43 while the no-testing scenario amounted to €12,053,291.17. It was estimated that the screening test improved the quality of life among the patients' relatives by 43.8 quality-adjusted life years (QALYs). The incremental cost-utility ratio (ICUR) was €31,621.33/QALY in the base case. The PSA showed that 89.12% of the simulations were below the €50,000/QALY threshold. Conclusion: Providing this screening test to HGEOC patients and their relatives is cost-effective and it allows one to identify a target population with high risk of cancer to provide effective prevention strategies. | es_ES |
dc.description.sponsorship | This study was funded by AstraZeneca Farmaceutica Spain. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Springer Science and Business Media LLC | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Materias Investigacion::Ciencias de la Salud::Oncología | es_ES |
dc.subject | BRCA1 gene | es_ES |
dc.subject | BRCA2 gene | es_ES |
dc.subject | Cancer screening test | es_ES |
dc.subject | Cost–utility analysis | es_ES |
dc.subject | Ovarian cancer | es_ES |
dc.subject | Quality-adjusted life years | es_ES |
dc.title | Cost–utility analysis of germline BRCA1/2 testing in women with high‑grade epithelial ovarian cancer in Spain | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.description.note | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. | es_ES |
dc.identifier.doi | 10.1007/s12094-018-02026-2 | - |
dadun.citation.endingPage | 1084 | es_ES |
dadun.citation.publicationName | Clinical and Translational Oncology | es_ES |
dadun.citation.startingPage | 1076 | es_ES |
dadun.citation.volume | 21 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.